Parschauer Karah's most recent trade in Tenaya Therapeutics Inc was a trade of 107,400 Stock Option (Right to buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 107,400 | 107,400 | - | - | Stock Option (Right to buy) | |
| Evolus Inc | Karah Parschauer | Director | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 12 Mar 2025 | 12,888 | 32,183 (0%) | 0% | 13.0 | 167,465 | Common Stock |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 11,146 | 11,146 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 7,364 | 45,071 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 18,443 | 88,133 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 42.10 per share. | 01 Mar 2025 | 12,846 | 75,287 (0%) | 0% | 42.1 | 540,817 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 26,074 | 26,074 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 14,494 | 69,690 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 42.93 per share. | 27 Feb 2025 | 2,230 | 55,751 (0%) | 0% | 42.9 | 95,734 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 42.75 per share. | 27 Feb 2025 | 760 | 54,991 (0%) | 0% | 42.8 | 32,490 | Common Stock |
| Tenaya Therapeutics Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 12 Jun 2024 | 9,806 | 57,981 (0%) | 0% | 45 | 441,270 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 31,400 | 31,400 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,800 | 69,782 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 53.76 per share. | 01 Mar 2024 | 3,756 | 67,340 (0%) | 0% | 53.8 | 201,923 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 957 | 70,739 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | Parschauer Karah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 9,377 | 9,377 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Parschauer Karah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 6,464 | 37,707 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | Karah Parschauer | Director | Sale of securities on an exchange or to another person at price $ 13.14 per share. | 30 Jan 2024 | 11,931 | 31,243 (0%) | 0% | 13.1 | 156,733 | Common Stock |
| Tenaya Therapeutics Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 29,532 | 29,532 | - | - | Stock Option (Right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 04 May 2023 | 4,378 | 51,982 (0%) | 0% | 45 | 197,010 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 39,400 | 39,400 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 22,000 | 59,101 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 01 Mar 2023 | 3,161 | 56,139 (0%) | 0% | 45.2 | 143,035 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,663 | 37,101 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 11,789 | 11,789 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 8,293 | 43,174 (0%) | 0% | 0 | Common Stock | |
| Anebulo Pharmaceuticals Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2022 | 30,425 | 30,425 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 62.95 per share. | 07 Mar 2022 | 5,140 | 34,438 (0%) | 0% | 63.0 | 323,563 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 24,900 | 24,900 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 14,000 | 39,578 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 66.62 per share. | 01 Mar 2022 | 2,886 | 25,472 (0%) | 0% | 66.6 | 192,265 | Common Stock |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 22,727 | 22,727 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 15,568 | 34,881 (0%) | 0% | 0 | Common Stock | |
| Tenaya Therapeutics Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 19,495 | 19,495 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 81.14 per share. | 14 Oct 2021 | 310 | 28,358 (0%) | 0% | 81.1 | 25,153 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 100.65 per share. | 08 Sep 2021 | 7,336 | 28,668 (0%) | 0% | 100.6 | 738,368 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 7,336 | 17,664 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 08 Sep 2021 | 7,336 | 36,004 (0%) | 0% | 54.5 | 399,812 | Common Stock |
| Arcturus Therapeutics Hold... | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 113.67 per share. | 06 May 2021 | 313 | 29,997 (0%) | 0% | 113.7 | 35,579 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 5,500 | 29,561 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 4,636 | 34,197 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 138.17 per share. | 01 Mar 2021 | 3,970 | 30,227 (0%) | 0% | 138.2 | 548,535 | Common Stock |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 19,313 | 19,313 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 30 Oct 2020 | 9,903 | 33,871 (0%) | 0% | 54.5 | 539,714 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 100.12 per share. | 30 Oct 2020 | 9,903 | 24,061 (0%) | 0% | 100.1 | 991,488 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 9,903 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 28 Oct 2020 | 97 | 23,968 (0%) | 0% | 100 | 9,700 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.51 per share. | 28 Oct 2020 | 97 | 24,065 (0%) | 0% | 54.5 | 5,287 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2020 | 97 | 34,903 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 88.00 per share. | 14 Oct 2020 | 325 | 23,968 (0%) | 0% | 88 | 28,600 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 08 Oct 2020 | 10,000 | 24,293 (0%) | 0% | 95 | 950,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 10,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 08 Oct 2020 | 10,000 | 34,293 (0%) | 0% | 54.5 | 545,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 06 Oct 2020 | 10,000 | 24,293 (0%) | 0% | 90 | 900,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2020 | 10,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 06 Oct 2020 | 10,000 | 34,293 (0%) | 0% | 48.4 | 484,300 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 85.00 per share. | 23 Sep 2020 | 10,000 | 24,293 (0%) | 0% | 85 | 850,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2020 | 10,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 23 Sep 2020 | 10,000 | 34,293 (0%) | 0% | 48.4 | 484,300 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 10,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 88.44 per share. | 17 Aug 2020 | 10,000 | 26,663 (0%) | 0% | 88.4 | 884,400 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 17 Aug 2020 | 10,000 | 36,663 (0%) | 0% | 54.5 | 545,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 88.39 per share. | 17 Aug 2020 | 2,370 | 24,293 (0%) | 0% | 88.4 | 209,484 | Common Stock |